402 related articles for article (PubMed ID: 19038008)
21. Monoclonal antibody FMC7 detects a conformational epitope on the CD20 molecule: evidence from phenotyping after rituxan therapy and transfectant cell analyses.
Serke S; Schwaner I; Yordanova M; Szczepek A; Huhn D
Cytometry; 2001 Apr; 46(2):98-104. PubMed ID: 11309819
[TBL] [Abstract][Full Text] [Related]
22. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.
Davis TA; Grillo-López AJ; White CA; McLaughlin P; Czuczman MS; Link BK; Maloney DG; Weaver RL; Rosenberg J; Levy R
J Clin Oncol; 2000 Sep; 18(17):3135-43. PubMed ID: 10963642
[TBL] [Abstract][Full Text] [Related]
23. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis.
Golay J; Zaffaroni L; Vaccari T; Lazzari M; Borleri GM; Bernasconi S; Tedesco F; Rambaldi A; Introna M
Blood; 2000 Jun; 95(12):3900-8. PubMed ID: 10845926
[TBL] [Abstract][Full Text] [Related]
24. Transformation of Hodgkin's disease to high-grade B-cell lymphoma: remission after Rituximab monotherapy.
Kirchner EM; Ebsen M; Kirchner J; Theegarten D; Voigtmann R
Ann Oncol; 2001 Aug; 12(8):1169-71. PubMed ID: 11583202
[TBL] [Abstract][Full Text] [Related]
25. Monoclonal antibody therapy for B-cell lymphoma: clinical trials of an anti-CD20 monoclonal antibody for B-cell lymphoma in Japan.
Tobinai K
Int J Hematol; 2002 Dec; 76(5):411-9. PubMed ID: 12512835
[TBL] [Abstract][Full Text] [Related]
26. Loss of CD20 antigen expression after rituximab therapy of CD20 positive B cell lymphoma (diffuse large B cell extranodal marginal zone lymphoma combination): a case report and review of the literature.
Duman BB; Sahin B; Ergin M; Guvenc B
Med Oncol; 2012 Jun; 29(2):1223-6. PubMed ID: 21805377
[TBL] [Abstract][Full Text] [Related]
27. Rituximab for aggressive non-Hodgkin's lymphomas relapsing after or refractory to autologous stem cell transplantation.
Pan D; Moskowitz CH; Zelenetz AD; Straus D; Kewalaramani T; Noy A; Qin J; Teruya-Feldstein J; Portlock CS
Cancer J; 2002; 8(5):371-6. PubMed ID: 12416894
[TBL] [Abstract][Full Text] [Related]
28. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.
Coiffier B; Haioun C; Ketterer N; Engert A; Tilly H; Ma D; Johnson P; Lister A; Feuring-Buske M; Radford JA; Capdeville R; Diehl V; Reyes F
Blood; 1998 Sep; 92(6):1927-32. PubMed ID: 9731049
[TBL] [Abstract][Full Text] [Related]
29. Comparison of CD20 expression in B-cell lymphoma between newly diagnosed, untreated cases and those after rituximab treatment.
Miyoshi H; Arakawa F; Sato K; Kimura Y; Kiyasu J; Takeuchi M; Yoshida M; Ichikawa A; Ishibashi Y; Nakamura Y; Nakashima S; Niino D; Sugita Y; Ohshima K
Cancer Sci; 2012 Aug; 103(8):1567-73. PubMed ID: 22500644
[TBL] [Abstract][Full Text] [Related]
30. Treatment of primary cutaneous follicular centre lymphoma with rituximab: a report of two cases.
Kennedy GA; Blum R; McCormack C; Prince HM
Australas J Dermatol; 2004 Feb; 45(1):34-7. PubMed ID: 14961906
[TBL] [Abstract][Full Text] [Related]
31. Cutaneous B-cell lymphoma with loss of CD20 immunoreactivity after rituximab therapy.
Clarke LE; Bayerl MG; Ehmann WC; Helm KF
J Cutan Pathol; 2003 Aug; 30(7):459-62. PubMed ID: 12859745
[TBL] [Abstract][Full Text] [Related]
32. Predictive significance of the cut-off value of CD20 expression in patients with B-cell lymphoma.
Horvat M; Kloboves Prevodnik V; Lavrencak J; Jezersek Novakovic B
Oncol Rep; 2010 Oct; 24(4):1101-7. PubMed ID: 20811695
[TBL] [Abstract][Full Text] [Related]
33. Lymphoplasmacytic lymphoma/immunocytoma: towards a disease-targeted treatment?
Clavio M; Quintino S; Venturino C; Ballerini F; Varaldo R; Gatto S; Galbusera V; Garrone A; Grasso R; Canepa L; Miglino M; Pierri I; Gobbi M
J Exp Clin Cancer Res; 2001 Sep; 20(3):351-8. PubMed ID: 11718214
[TBL] [Abstract][Full Text] [Related]
34. The absence of CD20 messenger RNA in recurrent cutaneous B-cell lymphoma following rituximab therapy.
Rawal YB; Nuovo GJ; Frambach GE; Porcu P; Baiocchi RA; Magro CM
J Cutan Pathol; 2005 Oct; 32(9):616-21. PubMed ID: 16176299
[TBL] [Abstract][Full Text] [Related]
35. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression.
Davis TA; Czerwinski DK; Levy R
Clin Cancer Res; 1999 Mar; 5(3):611-5. PubMed ID: 10100713
[TBL] [Abstract][Full Text] [Related]
36. Identification of CD20 C-terminal deletion mutations associated with loss of CD20 expression in non-Hodgkin's lymphoma.
Terui Y; Mishima Y; Sugimura N; Kojima K; Sakurai T; Mishima Y; Kuniyoshi R; Taniyama A; Yokoyama M; Sakajiri S; Takeuchi K; Watanabe C; Takahashi S; Ito Y; Hatake K
Clin Cancer Res; 2009 Apr; 15(7):2523-30. PubMed ID: 19276251
[TBL] [Abstract][Full Text] [Related]
37. Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance.
Hiraga J; Tomita A; Sugimoto T; Shimada K; Ito M; Nakamura S; Kiyoi H; Kinoshita T; Naoe T
Blood; 2009 May; 113(20):4885-93. PubMed ID: 19246561
[TBL] [Abstract][Full Text] [Related]
38. Durable remission in recurrent T-cell-rich B-cell lymphoma with the anti-CD20 antibody rituximab.
Natkunam Y; Stanton TS; Warnke RA; Horning SJ
Clin Lymphoma; 2001 Dec; 2(3):185-7. PubMed ID: 11779297
[TBL] [Abstract][Full Text] [Related]
39. The predictive significance of CD20 expression in B-cell lymphomas.
Prevodnik VK; Lavrenčak J; Horvat M; Novakovič BJ
Diagn Pathol; 2011 Apr; 6():33. PubMed ID: 21486448
[TBL] [Abstract][Full Text] [Related]
40. IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients.
Nguyen DT; Amess JA; Doughty H; Hendry L; Diamond LW
Eur J Haematol; 1999 Feb; 62(2):76-82. PubMed ID: 10052709
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
